Harmony Biosciences Holdings Inc (HRMY) concluded trading on Wednesday at a closing price of $32.48, with 0.42 million shares of worth about $13.73 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.28% during that period and on June 18, 2025 the price saw a gain of about 0.03%. Currently the company’s common shares owned by public are about 57.39M shares, out of which, 43.61M shares are available for trading.
Stock saw a price change of -7.57% in past 5 days and over the past one month there was a price change of -9.55%. Year-to-date (YTD), HRMY shares are showing a performance of -5.61% which increased to 11.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $26.47 but also hit the highest price of $41.61 during that period. The average intraday trading volume for Harmony Biosciences Holdings Inc shares is 723.76K. The stock is currently trading -5.32% below its 20-day simple moving average (SMA20), while that difference is up 0.37% for SMA50 and it goes to -6.07% lower than SMA200.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) currently have 57.39M outstanding shares and institutions hold larger chunk of about 78.52% of that.
The stock has a current market capitalization of $1.87B and its 3Y-monthly beta is at 0.87. PE ratio of stock for trailing 12 months is 12.38, while it has posted earnings per share of $2.62 in the same period. Its PEG reads 0.49 and has Quick Ratio of 3.63 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HRMY, volatility over the week remained 0.66% while standing at 1.78% over the month.
Stock’s fiscal year EPS is expected to rise by 24.67% while it is estimated to increase by 28.04% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on June 02, 2025 offering an Outperform rating for the stock and assigned a target price of $61 to it. Coverage by Deutsche Bank stated Harmony Biosciences Holdings Inc (HRMY) stock as a Buy in their note to investors on February 11, 2025, suggesting a price target of $55 for the stock. Stock get a Buy rating from UBS on September 10, 2024.
